Works matching IS 1021335X AND DT 2024 AND VI 52 AND IP 5

Results: 17

Repurposing propofol for breast cancer therapy through promoting apoptosis and arresting cell cycle.

Published in:

Oncology Reports, 2024, v. 52, n. 5, p. N.PAG, doi. 10.3892/or.2024.8814

By:

Sun, Peng;
Huang, Hanqing;
Ma, Jian-Chao;
Feng, Binyang;
Zhang, Yiqing;
Qin, Genggeng;
Zeng, Weian;
Cui, Zhong-Kai

Publication type:

Article

miR‑25‑3p serves as an oncogenic in colorectal cancer cells by regulating the ubiquitin ligase FBXW7 function.

Published in:

Oncology Reports, 2024, v. 52, n. 5, p. N.PAG, doi. 10.3892/or.2024.8812

By:

Chen, Yanbin;
Chen, Bingchen;
Tu, Shiliang;
Yuan, Hang

Publication type:

Article

[Retracted] Tetramethylpyrazine inhibits prostate cancer progression by downregulation of forkhead box M1.

Published in:

Oncology Reports, 2024, v. 52, n. 5, p. N.PAG, doi. 10.3892/or.2024.8811

By:

Zhou, Yi;
Ji, Zhigang;
Yan, Weigang;
Zhou, Zhien;
Li, Hanzhong;
Xiao, Yu

Publication type:

Article

Engineered extracellular vesicles with polypeptide for targeted delivery of doxorubicin against EGFR‑positive tumors.

Published in:

Oncology Reports, 2024, v. 52, n. 5, p. N.PAG, doi. 10.3892/or.2024.8813

By:

Yang, Yuqing;
Wang, Fang;
Li, Yuqin;
Chen, Ruxi;
Wang, Xiangyu;
Chen, Jiahong;
Lin, Xi;
Zhang, Haipeng;
Huang, Youwei;
Wang, Rui

Publication type:

Article

[Retracted] MicroRNA-124-3p inhibits the growth and metastasis of nasopharyngeal carcinoma cells by targeting STAT3.

Published in:

Oncology Reports, 2024, v. 52, n. 5, p. N.PAG, doi. 10.3892/or.2024.8807

By:

Xu, Shan;
Zhao, Ning;
Hui, Lian;
Song, Min;
Miao, Zi-Wei;
Jiang, Xue-Jun

Publication type:

Article

Lung cancer and obesity: A contentious relationship (Review).

Published in:

Oncology Reports, 2024, v. 52, n. 5, p. N.PAG, doi. 10.3892/or.2024.8817

By:

Georgakopoulou, Vasiliki Epameinondas;
Lempesis, Ioannis G.;
Trakas, Nikolaos;
Sklapani, Pagona;
He, Yutong;
Spandidos, Demetrios A.

Publication type:

Article

The molecular mechanisms of chemotherapeutic resistance in tumors (Review).

Published in:

Oncology Reports, 2024, v. 52, n. 5, p. N.PAG, doi. 10.3892/or.2024.8816

By:

Weng, Xin;
Zeng, Wei-Hong;
Zhong, Li-Yuan;
Xie, Li-Hua;
Ge, Wen-Jun;
Lai, Zhen;
Qin, Qin;
Liu, Peng;
Cao, De-Liang;
Zeng, Xi

Publication type:

Article

Enhanced capture system for mesenchymal‑type circulating tumor cells using a polymeric microfluidic device 'CTC‑Chip' incorporating cell‑surface vimentin.

Published in:

Oncology Reports, 2024, v. 52, n. 5, p. N.PAG, doi. 10.3892/or.2024.8815

By:

Kanayama, Masatoshi;
Yoneda, Kazue;
Kuwata, Taiji;
Mori, Masataka;
Manabe, Takehiko;
Oyama, Rintaro;
Matsumiya, Hiroki;
Takenaka, Masaru;
Kuroda, Koji;
Ohnaga, Takashi;
Tanaka, Fumihiro

Publication type:

Article

Routes and molecular mechanisms of central nervous system involvement in acute myeloid leukemia (Review).

Published in:

Oncology Reports, 2024, v. 52, n. 5, p. N.PAG, doi. 10.3892/or.2024.8805

By:

Chen, Liucui;
Zeng, Piaorong;
Tang, Huifang;
Chen, Gang;
Xie, Juan;
Yang, Xiaoyan;
Lei, Xiaoyong

Publication type:

Article

The role of lncRNA binding to RNA‑binding proteins to regulate mRNA stability in cancer progression and drug resistance mechanisms (Review).

Published in:

Oncology Reports, 2024, v. 52, n. 5, p. N.PAG, doi. 10.3892/or.2024.8801

By:

Zhang, Nianjie;
Wen, Kunming

Publication type:

Article

Progress in antitumor mechanisms and applications of phenformin (Review).

Published in:

Oncology Reports, 2024, v. 52, n. 5, p. N.PAG, doi. 10.3892/or.2024.8810

By:

Zhong, Qi;
Li, Duo;
Yang, Xiao-Ping

Publication type:

Article

[Retracted] RNAi‑mediated EZH2 depletion decreases MDR1 expression and sensitizes multidrug‑resistant hepatocellular carcinoma cells to chemotherapy.

Published in:

Oncology Reports, 2024, v. 52, n. 5, p. N.PAG, doi. 10.3892/or.2024.8809

By:

Tang, Bo;
Zhang, Yi;
Liang, Rui;
Gao, Zhenming;
Sun, Deguang;
Wang, Liming

Publication type:

Article

The combination of a PTP1B inhibitor, TNFR2 blocker, and PD‑1 antibody suppresses the progression of non‑small cell lung cancer tumors by enhancing immunocompetence.

Published in:

Oncology Reports, 2024, v. 52, n. 5, p. N.PAG, doi. 10.3892/or.2024.8808

By:

Gui, Huan;
Nie, Yujie;
Yuan, Haohua;
Jing, Qianyu;
Li, Linzhao;
Zhu, Lan;
Chen, Shuanghui;
Wang, Mengjiao;
Wan, Quan;
Lv, Hang;
Nie, Yingjie;
Zhang, Xiangyan

Publication type:

Article

Antitumor activities of anti‑CD44 monoclonal antibodies in mouse xenograft models of esophageal cancer.

Published in:

Oncology Reports, 2024, v. 52, n. 5, p. N.PAG, doi. 10.3892/or.2024.8806

By:

Ishikawa, Kenichiro;
Suzuki, Hiroyuki;
Ohishi, Tomokazu;
Nakamura, Takuro;
Yanaka, Miyuki;
Li, Guanjie;
Tanaka, Tomohiro;
Ohkoshi, Akira;
Kawada, Manabu;
Kaneko, Mika K.;
Katori, Yukio;
Kato, Yukinari

Publication type:

Article

[Corrigendum] Omi/HtrA2 pro-apoptotic marker differs in various hepatocellular carcinoma cell lines owing to ped/pea-15 expression level.

Published in:

Oncology Reports, 2024, v. 52, n. 5, p. N.PAG, doi. 10.3892/or.2024.8804

By:

Xu, Zongquan;
Chen, Yu;
Xu, Guohui;
Peng, Cheng;
Liu, Enyu;
Li, Yunguang;
Niu, Jun;
Li, Changhai

Publication type:

Article

Role and functional mechanisms of IL‑17/IL‑17R signaling in pancreatic cancer (Review).

Published in:

Oncology Reports, 2024, v. 52, n. 5, p. N.PAG, doi. 10.3892/or.2024.8803

By:

Liu, Wanli;
Wang, Xianze;
Wu, Wenming

Publication type:

Article

[Retracted] miRNA‑490‑3p promotes the metastatic progression of invasive ductal carcinoma.

Published in:

Oncology Reports, 2024, v. 52, n. 5, p. N.PAG, doi. 10.3892/or.2024.8802

By:

Lu, Ning;
Zhang, Mei;
Lu, Lu;
Liu, Yan-Zhao;
Zhang, Hai-Hong;
Liu, Xiao-Dong

Publication type:

Article